Ignite Creation Date:
2025-12-24 @ 6:28 PM
Ignite Modification Date:
2026-01-29 @ 3:51 AM
Study NCT ID:
NCT04920968
Status:
RECRUITING
Last Update Posted:
2025-04-24
First Post:
2021-04-25
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 "OVERALL"
Sponsor:
Maria Sklodowska-Curie National Research Institute of Oncology
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
20-NIO-0002
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | OTHER | View |